Jacobs, Heidi I. L. http://orcid.org/0000-0001-7620-3822
Hedden, Trey
Schultz, Aaron P.
Sepulcre, Jorge
Perea, Rodrigo D.
Amariglio, Rebecca E.
Papp, Kathryn V.
Rentz, Dorene M.
Sperling, Reisa A.
Johnson, Keith A.
Article History
Received: 6 June 2017
Accepted: 4 December 2017
First Online: 5 February 2018
Competing interests
: A.S. has been a paid consultant for Janssen Pharmaceuticals and Biogen. K.P. has served as a paid consultant for Biogen.D. Rentz has done consulting for Eli Lilly and served on the Scientific Advisory Board for Neurotrack. K.J. has served as paid consultant for Bayer, GE Healthcare, Janssen Alzheimer’s Immunotherapy, Siemens Medical Solutions, Genzyme, Novartis, Biogen, Roche, ISIS Pharma, AZTherapy, GEHC, Lundberg and Abbvie; and he is a site co-investigator for Lilly/Avid, Janssen Immunotherapy and Pfizer. R.S. has served as a paid consultant for Abbvie, Biogen, Bracket, Genentech, Lundbeck, Roche and Sanofi; has served as co-investigator for Avid, Eli Lilly and Janssen Alzheimer Immunotherapy clinical trials; and has spoken at symposia sponsored by Eli Lilly, Biogen and Janssen. R.S. receives research support from Janssen Pharmaceuticals and Eli Lilly and Co.; these relationships are not related to the content in the manuscript.